| 前收市價 | 52.89 |
| 開市 | 53.22 |
| 買盤 | 0.00 x 0 |
| 賣出價 | 0.00 x 0 |
| 今日波幅 | 50.00 - 53.23 |
| 52 週波幅 | 42.63 - 58.97 |
| 成交量 | |
| 平均成交量 | 1,744,154 |
| 市值 | 133.327十億 |
| Beta 值 (5 年，每月) | 0.42 |
| 市盈率 (最近 12 個月) | 29.08 |
| 每股盈利 (最近 12 個月) | 1.79 |
| 業績公佈日 | 2024年10月25日 |
| 遠期股息及收益率 | 2.04 (3.85%) |
| 除息日 | 2024年5月09日 |
| 1 年預測目標價 | 62.69 |
Investor's Business DailyIs Novavax Stock A Sell After An Unexpected Side Effect Torpedoed Its Testing Plans?
Novavax stock took a hit in mid-October after the FDA placed its request to begin testing two new products on hold. Is NVAX stock a sell?
BloombergHow Sanofi Was Caught in The Middle of a €16 Billion Public Brawl
(Bloomberg) -- After a year-long takeover battle for the owner of France’s best-selling painkiller, Sanofi’s decision to sell its over-the-counter business to a US buyout firm descended into mudslinging, public rebukes and political discord.Most Read from BloombergBooming Cambridge Exposes England’s Widening Wealth GapOman Sees an Urban Future Distinct From Dubai and Abu DhabiClimate Change Is Killing Buildings in Slow MotionRobotaxis Are No Friend of Public TransportationTransportation Policy G
ZacksThe Zacks Analyst Blog Highlights Johnson & Johnson, Pfizer, Roche, AbbVie and Sanofi
Johnson & Johnson, Pfizer, Roche, AbbVie and Sanofi are included in this Analyst Blog.
